Current Vacancies
-
Key details
- Location UK DRI at Imperial
- Salary: £48,246 - £58,318 per annum
About the role
We are looking to recruit a Clinical Project Manager to run an exciting Medical Research Council (MRC)-funded Experimental Medicine study, “N,N-Dimethyltryptamine (DMT) for Disorders of Consciousness (DoC)” (DMT-DoC). In people with DoC, this study will investigate the effects of intravenous DMT administration on measures of neural complexity, neuroplasticity, and awareness.
You will primarily be working to deliver the DMT-DoC study. This placebo-controlled study involves administering intravenous DMT and a saline placebo to patients with DoC. We will record electroencephalography (EEG) alongside other physiological and behavioural measures before, during, and after drug/placebo administration.
You will work in the Computational Neurology group of academic neurologist Dr Gregory Scott, within the Department of Brain Sciences, with a team of collaborators including experts in clinical neurology, psychedelics, neuropsychopharmacology, DoC, EEG, computer science, and neurophysiology.
What you would be doing
You will be responsible for all aspects of study management. This will include involvement and coordination of study set-up, in close liaison with Dr Scott. You will lead on the development of study documentation, regulatory submissions, monitoring progress and performance of the study and recruitment from participant identification centres, ensuring efficient recruitment and reliable data collection. This will be achieved through implementing / adapting established procedures to ensure the studies are conducted in accordance with contractual agreements, study protocol, study-specific processes and systems, SOPs, regulatory and ethical requirements and ICH-GCP guidelines, as well as delivered to time and within budget constraints. You will liaise closely with the participant-facing staff, including the Research Assistant, Post-doctoral Research Associate, trial medics, and psychedelics and brain injury specialists. You will also support the coordination of patient and public involvement and engagement (PPIE) and study monitoring activities, and attracting further research funding to the group.
This is an exciting opportunity to work on a study that could pave the way to a new class of treatment for DoC and improve our understanding of the neural mechanisms of consciousness.
What we are looking for
You should have experience in the coordination or management of biomedical or clinical research studies (preferably within a university, NHS, or research organisation setting). You should have experience of clinical research delivery and strong organisational skills. You must be able to build effective working relationships with a wide range of stakeholders, and have an understanding of Patient and Public Involvement and Engagement (PPIE) in clinical research.
Further information
This is a part-time (50% FTE), fixed term post until 31 March 2030. You will be based principally at the Hammersmith and White City Campuses, in Dr Scott’s group, and will be expected to spend 60% of your time on-site in line with Imperial’s Work Location framework.
You will be expected to travel between sites, and also potentially to collaborating research sites, e.g., The Royal Hospital for Neurodisability, Putney.
-
Key details
- Location UK DRI at Edinburgh
This 4-year PhD project is part of a competition funded by EASTBIO BBSRC Doctoral Training Partnership (DTP).
In the rapidly evolving field of medical imaging, the integration and analysis of data from diverse acquisition systems present a critical challenge. Variability in imaging parameters and modalities hampers the consistency and reliability of analyses when combining data from different clinical settings and analysing longitudinal trajectories. Current harmonisation techniques are suboptimal in clinical settings. Phenotypes from images acquired with the most common protocol and under the scanners at major hospitals can bias automated pipelines, unfairly impacting patients imaged with disease-specific acquisition protocols and/or on scanners at health centres.
Another source of bias is caused by the population sample. Different levels of prevalence of diseases that reflect in structural brain changes also bias computational brain analyses. Automated phenotype extraction methods are often developed and validated in relatively homogeneous research datasets, whereas routine clinical imaging encompasses much greater variation in anatomy and pathology. The extent to which this heterogeneity affects measurement reliability, reference trajectories and comparability across datasets remains poorly characterised.
This project has the following aims:
1. Develop and validate robust extraction pipelines for technically challenging imaging phenotypes from heterogeneous routine clinical images: fractal cortical complexity, brain health index, white matter damage, brain volumes, white matter hyperintensities, and infarcts.
2. Quantify the influence of scanner, sequence, imaging modality, and acquisition parameters on each phenotype and develop harmonisation/QC strategies that preserve biological age- and sex-related variation.
3. Derive age- and sex-stratified clinical reference distributions for these phenotypes, with particular emphasis on measures for which large-scale reference values do not currently exist, and compare them with those acquired from research populations.
4. Test the reproducibility and clinical informativeness of these reference trajectories across independent datasets and diagnostic groups.
The student will receive training in medical image processing, big data analyses, working in the safe heaven, and advanced statistics. The principal supervisor will give day-to-day supervision in brain image processing and analysis methods, and the harmonisation of brain imaging data.
Funding Notes
This opportunity is open to UK and international students and provides funding covering stipend and UK level tuition fees.
-
Key details
- Location UK DRI at Imperial
- Salary: PhD position includes a tax-free stipend (for guidance, the UKRI London rate 2026/27 is £23,805) and UK/Home fees for 3.5 years.
The project
Cerebral small vessel disease (SVD) is a major cause of stroke and vascular dementia, and a key contributor to Alzheimer's disease. SVD is highly heritable, but most genetic risk variants lie in non-coding DNA, and how they disrupt gene regulation is largely unknown. This project will build the first integrative map of gene regulatory mechanisms in SVD, linking human genetics to molecular function. The aim is to find new blood biomarkers and genetically supported drug targets.
You will lead the analysis of a unique, deeply phenotyped cohort: 147 longitudinally followed SVD patients from the Mild Stroke Study 2 (MSS2). The cohort has genotyping, plasma proteomics, brain imaging, blood–brain barrier measures and 9 years of clinical follow-up. New DNA methylation (EPIC array) and RNA-seq data will be generated for the project. You will compare these with matched controls from the AIRWAVE cohort (~700 samples) and the Lothian Birth Cohort 1936.
- Aim 1 (years 1–2): Find DNA methylation and gene expression changes linked to SVD subtypes, dementia progression, polygenic risk, cardiovascular risk factors and epigenetic ageing.
- Aim 2 (years 3–4): Prioritise causal genes and variants. Methods include meQTL/eQTL analysis, multi-trait analysis with cardiovascular traits and other dementias, colocalisation and Mendelian randomisation. You will integrate the results with histone modification (CUT&Tag), single-cell multiome and proteomic data.
This is a computational (dry-lab) PhD. You will receive training in:
- statistical and population genetics
- epigenomics and multi-omic integration
- causal inference (Mendelian randomisation)
- reproducible analysis on high-performance computing
Training is provided by an interdisciplinary team spanning functional genomics, genetic epidemiology and clinical neuroimaging.
Supervisory team
- Dr Alexi Nott, Imperial College London (functional epigenomics and gene prioritisation)
- Prof Joanna Wardlaw, University of Edinburgh (clinical SVD and stroke, MSS2 cohort)
- Dr Axel Montagne, University of Edinburgh (vascular biomarkers, blood–brain barrier)
- Prof Abbas Dehghan, Imperial College London (genetic epidemiology, QTL analysis)
- Dr Fotios Koskeridis, Imperial College London (multi-trait genetics, cardiovascular traits)
Who we're looking for
- A first or upper-second class degree (or equivalent) in genetics, genomics, bioinformatics, computational biology, statistics, epidemiology, data science, neuroscience or a related quantitative discipline. A relevant Master's degree is desirable but not essential.
- Essential: programming experience in R and/or Python, and a strong interest in using data to understand human disease.
- Desirable: experience with Unix/HPC environments, statistical genetics (GWAS, QTL, Mendelian randomisation), omics data analysis (methylation arrays, RNA-seq, epigenomics) or large cohort datasets.
- You do not need wet-lab experience.
Funding
The studentship covers 4 years of:
- home tuition fees
- a tax free stipend, at least equal to the UKRI London rates (for 2026/27 this is £23,805)
- £5,000 per year for research costs
- £1,000 per year for conference travel
Additional funds can also be applied for to support training and career development.
Eligibility: home fee status only. The studentship covers home-rate tuition fees only, so we can only consider applicants who qualify for home fee status.